| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| FTSE EPRA Europe Ex UK Dividend + | XIAFLEX | Adhesive Capsulitis | Phase 2 | Intralesional injection | Orthopedic | |
| FTSE EPRA Europe Ex UK Dividend + | Collagenase Clostridium Histolyticum (CCH) | Adhesive capsulitis (AC) of the shoulder | Phase 2 | Intralesional | Orthopedic | |
| Fulcrum Therapeutics Inc. | Losmapimod | COVID-19 | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| Fulcrum Therapeutics Inc. | Losmapimod - (ReDUX4) | Facioscapulohumeral muscular dystrophy (FSHD) | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
| Fulcrum Therapeutics Inc. | Losmapimod | COVID-19 | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| Fulcrum Therapeutics Inc. | Losmapimod - (REACH) | Facioscapulohumeral muscular dystrophy (FSHD) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Galapagos NV | GLPG3667 - (GALARISSO) | Duchenne Muscular (DM) | Phase 2 | Data Released | Oral | Genetic Disorder |
| Galapagos NV | Filgotinib - (OLINGUITO) | Ankylosing spondylitis | Phase 2 | Enrollment Initiation | Oral | Immunology: Anti-TNF |